Global. Reckitt Benckiser's sales are expected to slowly accelerate in 2018, helped by recoveries at Mead Johnson and the group's base business.Reckitt Benckiser Sales to Slowly Accelerate in 2018: Liberum -- Market Talk 25 October 2017 03:43 Dow Jones Institutional News 0843 GMT - Reckitt Benckiser's like-for-like sales are expected to slowly accelerate in 2018, helped by recoveries at Mead Johnson and the group's base business, Liberum anticipates. The third quarter proved challenging for the owner of brands including Durex and Airwick, as the effects of a cyber-attack and an end-market slowdown weighed on growth, prompting the company to cut full-year sales guidance. Liberum regards the company as a consumer health powerhouse due to the acquisition of Mead, which has increased the group's exposure to a sector experiencing attractive structural growth trends. The brokerage keeps a buy recommendation on the stock, with a target price of GBP80, down from GBP87.(adria.calatayudvaello@dowjones.com)http://hogar.intelect.com.mx/notes/global-reckitt-benckisers-sales-are-expected-to-slowly-accelerate-in-2018-helped-by-recoveries-at-mead-johnson-and-the-groups-base-businesshttp://hogar.intelect.com.mx/@@site-logo/logoAllen.png
Global. Reckitt Benckiser's sales are expected to slowly accelerate in 2018, helped by recoveries at Mead Johnson and the group's base business.
Reckitt Benckiser Sales to Slowly Accelerate in 2018: Liberum -- Market Talk 25 October 2017 03:43 Dow Jones Institutional News 0843 GMT - Reckitt Benckiser's like-for-like sales are expected to slowly accelerate in 2018, helped by recoveries at Mead Johnson and the group's base business, Liberum anticipates. The third quarter proved challenging for the owner of brands including Durex and Airwick, as the effects of a cyber-attack and an end-market slowdown weighed on growth, prompting the company to cut full-year sales guidance. Liberum regards the company as a consumer health powerhouse due to the acquisition of Mead, which has increased the group's exposure to a sector experiencing attractive structural growth trends. The brokerage keeps a buy recommendation on the stock, with a target price of GBP80, down from GBP87.(adria.calatayudvaello@dowjones.com)
Reckitt Benckiser Sales to Slowly Accelerate in 2018: Liberum -- Market Talk
25 October 2017
03:43
Dow Jones Institutional News
0843 GMT - Reckitt Benckiser's like-for-like sales are expected to slowly accelerate in 2018, helped by recoveries at Mead Johnson and the group's base business, Liberum anticipates. The third quarter proved challenging for the owner of brands including Durex and Airwick, as the effects of a cyber-attack and an end-market slowdown weighed on growth, prompting the company to cut full-year sales guidance. Liberum regards the company as a consumer health powerhouse due to the acquisition of Mead, which has increased the group's exposure to a sector experiencing attractive structural growth trends. The brokerage keeps a buy recommendation on the stock, with a target price of GBP80, down from GBP87.(adria.calatayudvaello@dowjones.com)
